(Q30592222)

25 June 2017

1 reference

title

What is new in the treatment of multiple sclerosis? (English)

1 reference

25 June 2017

0 references

Weinstock-Guttman B

1

1 reference

25 June 2017

Jacobs LD

series ordinal

2

1 reference

25 June 2017

publication date

1 March 2000

1 reference

25 June 2017

1 reference

25 June 2017

volume

59

1 reference

25 June 2017

issue

3

1 reference

25 June 2017

page(s)

401-410

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200059030-00002

25 June 2017

exact match

0 references

cites work

The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Cladribine in treatment of chronic progressive multiple sclerosis

1 reference

12 December 2020

High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations

1 reference

12 December 2020

Glucocorticosteroid therapy for multiple sclerosis: a critical review

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

12 December 2020

Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis

1 reference

12 December 2020

A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis

1 reference

12 December 2020

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

1 reference

12 December 2020

Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis

1 reference

12 December 2020

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group

1 reference

12 December 2020

Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs

1 reference

12 December 2020

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

1 reference

12 December 2020

Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration

1 reference

12 December 2020

Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis

1 reference

12 December 2020

Overview of azathioprine treatment in multiple sclerosis

1 reference

12 December 2020

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

1 reference

12 December 2020

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

1 reference

12 December 2020

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

1 reference

12 December 2020

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

12 December 2020

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

Interferon beta in the treatment of multiple sclerosis: mechanisms of action

1 reference

12 December 2020

Axonal transection in the lesions of multiple sclerosis

1 reference

12 December 2020

A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.

1 reference

12 December 2020

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

12 December 2020

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

10.2165/00003495-200059030-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

25 June 2017

1017432260

0 references

1 reference